Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report), retaining the price ...

Idiopathic pulmonary fibrosis (IPF), the most common phenotype of IIPs, has a prognosis that is influenced by a number of ...

周一，H.C. Wainwright重申了对Pliant Therapeutics (NASDAQ:PLRX)股票的买入评级，目标价维持在$38.00。该公司的乐观态度源于bexotegrast治疗特发性肺纤维化(IPF)的BEACON-IPF临床试验的进展。该试验正按计划进行，预计患者招募将在2025年第一季度结束。 BEACON-IPF试验是一项为期52周的研究，旨在评估bexotegrast ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

The primary focus is on the company’s bexotegrast, an αvß6/αvß1 integrin inhibitor, which is being developed for the treatment of idiopathic pulmonary fibrosis (IPF). The enrollment for the Phase 2b/3 ...

巴塞罗那官方公布了亚马尔和莱万多夫斯基的伤情，他们都将错过国家队的比赛。 巴萨官方宣布，亚马尔右脚踝韧带联合1级损伤，大约缺席2-3周，莱万多夫斯基腰部受伤，预计缺阵10天。

艾思瑞®作为全球仅有的两款获批且受指南推荐的特发性肺纤维化（IPF）治疗药物之一，填补了国内市场空白，为众多患者带来了新的治疗选择。这一突破性的成果得益于罗楹对研发创新的高度重视和持续投入，展现了康蒂尼药业在医药领域的深厚实力和创新能力。

近日，备受全球华人瞩目的2024年福布斯全球华人精英TOP 100榜单正式揭晓，康蒂尼药业董事会主席罗楹凭借其*的领导力和在医药创新领域的杰出贡献成功入选。这份荣誉不仅彰显了罗楹个人的*成就与不懈努力，更凸显了康蒂尼药业在医药行业的*地位和深远影响。

From November 2024 to March 2025, the new shipment preparation time is extended by up to 1 hour. Customers using FedEx International First® (IF), FedEx International Priority® Express (IPE), FedEx ...

“This will significantly modernise IPF’s Brisbane PDC capability, enabling us to meet our customers’ expectations well into the future. “The decision to relocate the PDC allows us to progress our ...

The ASX 200 stock had a good year on the chart but a mixed year in the business. Incitec Pivot's "transformation activities" ...